Business
Marina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael French
Marina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael French.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n \n \n Marina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael French\n \n \nMarina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael French\n \n BOTHELL, WA--(Marketwired - Jun 2, 2016) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announcd that J. Michael French, chairman of the board, president and chief executive officer, is resigning effective June 10, 2016 to pursue other opportunities. Current board member, Joseph W. Ramelli, will assume the roles of chairman of the board and acting chief executive officer. The board of directors is currently conducting a search for a new CEO.\n \"The Board thanks Mr. French for his efforts and leadership of Marina, including the transition of the company from an oligonucleotide therapeutics company to a late-stage therapeutics company, with the pending completion of our proposed agreement with Turing Pharmaceuticals for its late-stage intranasal ketamine program. We wish him well in his future endeavors,\" said Mr. Ramelli. \"The Board has already begun a search for a new Chief Executive Officer with the expertise and experience necessary to fully execute on the opportunity provided by the ketamine program.\"\n About Marina Biotech, Inc.\n Marina Biotech is an oligonucleotide therapeutics company with broad drug discovery technologies providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds, including messengerRNA therapeutics. These technologies were built via a roll-up strategy to discover and develop different types of nucleic acid therapeutics in order to modulate (up or down) a specific protein(s) which is either being produced too much or too little thereby causing a particular disease. We believe that the Marina Biotech technologies have unique strengths as a drug discovery engine for the development of nucleic acid-based therapeutics for rare and orphan diseases. Further, we believe Marina Biotech is the only company in the sector that has a delivery technology in human clinical trials with differentiated classes of payloads, through licensees ProNAi Therapeutics and Mirna T...